Eleven Biotherapeutics Inc. (NASDAQ:EBIO) announced its quarterly earnings results on Monday. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $1.08. Eleven Biotherapeutics had a negative return on equity of 207.40% and a negative net margin of 2,995.34%. The firm had revenue of $28.70 million for the quarter.

Shares of Eleven Biotherapeutics (NASDAQ:EBIO) opened at 2.62 on Monday. The firm has a 50-day moving average price of $2.29 and a 200-day moving average price of $2.66. Eleven Biotherapeutics has a 12 month low of $0.25 and a 12 month high of $5.97. The company’s market capitalization is $40.33 million.

Earnings History for Eleven Biotherapeutics (NASDAQ:EBIO)

In other news, Director Abbie Celniker sold 10,031 shares of the firm’s stock in a transaction that occurred on Wednesday, September 28th. The stock was sold at an average price of $3.00, for a total value of $30,093.00. Following the completion of the sale, the director now directly owns 409,915 shares of the company’s stock, valued at $1,229,745. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Ventures Fund 2007 L. Flagship sold 46,692 shares of the firm’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $4.18, for a total value of $195,172.56. The disclosure for this sale can be found here. 28.70% of the stock is owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in EBIO. Flagship Ventures Fund 2007 L.P. acquired a new stake in Eleven Biotherapeutics during the first quarter worth about $610,000. Flagship Ventures Fund IV L.P. acquired a new stake in Eleven Biotherapeutics during the first quarter worth about $469,000. Bank of New York Mellon Corp boosted its stake in Eleven Biotherapeutics by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 67,483 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 7,846 shares during the last quarter. Flagship Ventures Fund IV General Partner LLC acquired a new stake in Eleven Biotherapeutics during the second quarter worth about $2,464,000. Finally, Boxer Capital LLC acquired a new stake in Eleven Biotherapeutics during the second quarter worth about $1,670,000. 35.28% of the stock is owned by institutional investors.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

5 Day Chart for NASDAQ:EBIO

Receive News & Stock Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.